RAPT Therapeutics, Inc. (RAPT)

Market Cap	37.41M
Revenue (ttm)	n/a
Net Income (ttm)	-107.49M
Shares Out	34.96M
EPS (ttm)	-2.78
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	843,332
Open	1.060
Previous Close	1.070
Day's Range	1.020 - 1.100
52-Week Range	1.010 - 27.350
Beta	0.32
Analysts	Hold
Price Target	5.00 (+367.29%)
Earnings Date	Nov 12, 2024

About RAPT

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 31, 2019
• Employees: 131
• Stock Exchange: NASDAQ
• Ticker Symbol: RAPT
• Website: https://www.rapt.com

Analyst Forecast

According to 10 analysts, the average rating for RAPT stock is "Hold." The 12-month stock price forecast is $5.0, which is an increase of 367.29% from the latest price.

Price Target

$5.0

(367.29% upside)

Analyst Consensus: Hold